The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report

RATIONALE: Hepatocellular carcinoma (HCC) is a highly invasive cancer associated with high mortality rates. Although sorafenib is currently recommended as standard treatment for advanced HCC, its treatment efficacy is limited. Effective treatments for patients with advanced HCC that progresses on or...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Hong, Ma, Xiaojun, Zhao, Yaqin, Duo, Ji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023671/
https://www.ncbi.nlm.nih.gov/pubmed/29924049
http://dx.doi.org/10.1097/MD.0000000000011214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023671/
https://www.ncbi.nlm.nih.gov/pubmed/29924049
http://dx.doi.org/10.1097/MD.0000000000011214

Ejemplares similares